Mario Eisenberger

Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy.

Alan W Partin, A. Partin, P. Walsh, 2005, JAMA.

Interobserver variability in histologic evaluation of radical prostatectomy between central and local pathologists: findings of TAX 3501 multinational clinical trial.

Jonathan I. Epstein, J. Epstein, M. Eisenberger, 2011, Urology.

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.

David F Jarrard, Yu-Ning Wong, Nicholas J Vogelzang, 2015, The New England journal of medicine.

Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer.

Elizabeth Garrett-Mayer, Andrew J Armstrong, I. Tannock, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial.

David F Jarrard, Nicholas J Vogelzang, C. Kyriakopoulos, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Unmet needs in the prediction and detection of metastases in prostate cancer.

Oliver Sartor, Michael W Kattan, M. Kattan, 2013, The oncologist.